IN DEPTH

DCTs in 2023: New year’s resolutions for decentralised clinical trials

Are we entering the era of biologics for COPD?

CMO Moves: Regulatory catalysts for drug manufacturing-February

Manufacturing

‘Right shoring’ API production in Europe

Amidst rising inflation and ongoing drug shortages, is the EU is at risk of getting ‘right-shoring’ wrong?

Patient Access

Can Provention’s Tzield reach all T1D patients?

R&D

Inside the hunt for an Alzheimer’s disease vaccine

DCTs in 2023: New year’s resolutions for decentralised clinical trials

Are we entering the era of biologics for COPD?

CMO Moves: Regulatory catalysts for drug manufacturing-February

02/24/2023 16:07:29
  • Home | ‘Right shoring’ API production in Europe
  • In this issue
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Briefing
  • Industry news
  • The pharma industry briefing
  • HOF Sonderanlagenbau
  • BEA Technologies
  • Comment
  • 4D Molecular’s Fabry gene therapy program on FDA clinical hold
  • Price is key for wider market adoption of Amgen’s Amjevita
  • Wegovy: the latest weight loss fad
  • PROTAC development gains momentum, but clinical performance is poor
  • FDA head Califf on tighter accelerated approvals and lower drug prices
  • In Depth
  • ‘Right shoring’ API production in Europe
  • Provention’s Tzield can delay type 1 diabetes. But will it reach all patients?
  • DCTs in 2023: New year’s resolutions for decentralised clinical trials
  • Inside the hunt for an Alzheimer’s disease vaccine
  • Are we entering the era of biologics for COPD?
  • CMO Moves: Regulatory catalysts for drug manufacturing – February
  • Events
  • Next issue